Finivi Inc. decreased its position in Abbott Laboratories (NYSE:ABT – Free Report) by 71.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,175 shares of the healthcare product maker’s stock after selling 5,434 shares during the period. Finivi Inc.’s holdings in Abbott Laboratories were worth $272,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of ABT. Richards Merrill & Peterson Inc. increased its holdings in shares of Abbott Laboratories by 24.6% in the 4th quarter. Richards Merrill & Peterson Inc. now owns 9,568 shares of the healthcare product maker’s stock worth $1,199,000 after purchasing an additional 1,892 shares in the last quarter. 55 North Private Wealth LLC bought a new stake in shares of Abbott Laboratories in the 4th quarter worth $271,000. Davidson Investment Advisors increased its holdings in shares of Abbott Laboratories by 8.3% in the 4th quarter. Davidson Investment Advisors now owns 3,278 shares of the healthcare product maker’s stock worth $411,000 after purchasing an additional 250 shares in the last quarter. TD Waterhouse Canada Inc. increased its holdings in shares of Abbott Laboratories by 2.2% in the 4th quarter. TD Waterhouse Canada Inc. now owns 228,832 shares of the healthcare product maker’s stock worth $28,666,000 after purchasing an additional 4,971 shares in the last quarter. Finally, Tred Avon Family Wealth LLC increased its holdings in shares of Abbott Laboratories by 1.4% in the 4th quarter. Tred Avon Family Wealth LLC now owns 24,776 shares of the healthcare product maker’s stock worth $3,104,000 after purchasing an additional 344 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.
Abbott Laboratories News Roundup
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: New data and award for Abbott’s CancerGuard multi‑cancer early detection program reinforce long‑term diagnostics growth potential, supporting the company’s strategy to expand its multi‑biomarker testing footprint. Abbott’s CancerGuard Progress Adds New Dimension To Diagnostics Growth Story
- Positive Sentiment: Insider buying (including CEO purchases) cited in social/Quiver data is being highlighted by some investors as management showing confidence and as a potential vote of conviction amid the sell‑off. ABT Opinions on Q1 Earnings and Guidance Cut
- Neutral Sentiment: Market commentary and stock‑pick pieces are treating the drop as a potential buying opportunity for long‑term investors, noting diversified businesses and stable cash flow but cautioning about near‑term uncertainty. Has the Abbott Laboratories Sell-Off Finally Created an Entry Point?
- Neutral Sentiment: Comparisons to peers (e.g., Dexcom) frame Abbott as a different risk/reward — more diversified but less pure‑play growth — useful background for allocation decisions rather than an immediate price driver. Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom
- Negative Sentiment: Q1: revenue and adjusted EPS beat but management cut FY guidance (citing a mild flu season, acquisition costs and softer diagnostics), which triggered a sharp intraday sell‑off and heightened short‑term downside risk. ABT Opinions on Q1 Earnings and Guidance Cut
- Negative Sentiment: Numerous banks and brokerages trimmed price targets after the quarter (multiple cuts to mid‑$100s from higher levels), increasing near‑term analyst downside and amplifying selling pressure. Mizuho Cuts Abbott Laboratories Price Target to $115
Analysts Set New Price Targets
Check Out Our Latest Research Report on Abbott Laboratories
Insider Transactions at Abbott Laboratories
In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the purchase, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares in the company, valued at $4,526,575.12. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by corporate insiders.
Abbott Laboratories Price Performance
ABT opened at $96.06 on Tuesday. The company’s 50-day simple moving average is $107.59 and its two-hundred day simple moving average is $118.29. Abbott Laboratories has a 52-week low of $93.92 and a 52-week high of $139.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The stock has a market capitalization of $167.30 billion, a P/E ratio of 26.91, a P/E/G ratio of 1.58 and a beta of 0.79.
Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter in the prior year, the business earned $1.09 EPS. The business’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts predict that Abbott Laboratories will post 5.53 EPS for the current year.
Abbott Laboratories Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is 70.59%.
About Abbott Laboratories
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Further Reading
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
